PMID- 34968442
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 246
DP  - 2022 Apr
TI  - Risk and predictors of mortality after implantable cardioverter-defibrillator 
      implantation in patients with sarcoid cardiomyopathy.
PG  - 21-31
LID - S0002-8703(21)00491-9 [pii]
LID - 10.1016/j.ahj.2021.12.011 [doi]
AB  - BACKGROUND: Implantable cardioverter-defibrillators (ICDs) are recommended for 
      patients with cardiac sarcoidosis (CS) with an indication for pacing, prior 
      ventricular arrhythmias, cardiac arrest, or left ventricular ejection fraction 
      <35%, but data on outcomes are limited. METHODS: Using data from the National 
      Cardiovascular Data Registry ICD Registry between April 1, 2010 and December 31, 
      2015, we evaluated a propensity matched cohort of CS patients implanted with ICDs 
      versus non-ischemic cardiomyopathies (NICM). We compared mortality using 
      Kaplan-Meier survival curves and Cox proportional hazards models. RESULTS: We 
      identified 1,638 patients with CS and 8,190 propensity matched patients with 
      NICM. The rate of death at 1 and 2 years was similar in patients with CS and 
      patients with NICM (5.2% vs 5.4%, P = 0.75 and 9.0% vs 9.3%, P = 0.72, 
      respectively). After adjusting for other covariates, patients with CS had similar 
      mortality at 2 years after ICD implantations compared with NICM patients (RR 
      1.03, 95% CI 0.87-1.23). Among patients with CS, multivariable logistic 
      regression identified 6 factors significantly associated with increased 2-year 
      mortality: presence of heart failure (HR 1.92, 95% CI 1.44-3.22), New York Heart 
      Association (NYHA) Class III heart failure (HR 1.68, 95% CI 1.16-2.45), NYHA 
      Class IV heart failure (HR 3.08, 95% CI 1.49-6.39), atrial fibrillation/flutter 
      (HR 1.66, 95% CI 1.17-2.35), chronic lung disease (HR 1.64, 95% CI 1.17-2.29), 
      creatinine >2.0 mg/dL (HR 4.07, 95% CI 2.63-6.30), and paced rhythm (HR 2.66, 95% 
      CI 1.07-6.59). CONCLUSION: Mortality following ICD implantation was similar in CS 
      patients compared with propensity matched NICM patients. Presence of heart 
      failure, NYHA class, atrial fibrillation/flutter, chronic lung disease, renal 
      dysfunction, and paced rhythm at time of implantation were all predictors of 
      increased 2-year mortality among CS patients with ICDs.
CI  - Copyright (c) 2021. Published by Elsevier Inc.
FAU - Higgins, Angela Y
AU  - Higgins AY
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT.
FAU - Annapureddy, Amarnath R
AU  - Annapureddy AR
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT; Center for Outcomes Research and 
      Evaluation, Yale New Haven Health Services Corporation, New Haven, CT.
FAU - Wang, Yongfei
AU  - Wang Y
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT; Center for Outcomes Research and 
      Evaluation, Yale New Haven Health Services Corporation, New Haven, CT.
FAU - Minges, Karl E
AU  - Minges KE
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT; Center for Outcomes Research and 
      Evaluation, Yale New Haven Health Services Corporation, New Haven, CT; Department 
      of Health Administration and Policy, University of New Haven, West Haven, CT.
FAU - Bellumkonda, Lavanya
AU  - Bellumkonda L
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT.
FAU - Lampert, Rachel
AU  - Lampert R
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT.
FAU - Rosenfeld, Lynda E
AU  - Rosenfeld LE
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT.
FAU - Jacoby, Daniel L
AU  - Jacoby DL
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT.
FAU - Curtis, Jeptha P
AU  - Curtis JP
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT; Center for Outcomes Research and 
      Evaluation, Yale New Haven Health Services Corporation, New Haven, CT.
FAU - Miller, Edward J
AU  - Miller EJ
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT.
FAU - Freeman, James V
AU  - Freeman JV
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, CT; Center for Outcomes Research and 
      Evaluation, Yale New Haven Health Services Corporation, New Haven, CT. Electronic 
      address: james.freeman@yale.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211227
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
SB  - IM
MH  - *Atrial Fibrillation
MH  - Death, Sudden, Cardiac/epidemiology/etiology/prevention & control
MH  - *Defibrillators, Implantable
MH  - *Heart Failure/therapy
MH  - Humans
MH  - *Myocarditis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Sarcoidosis/complications
MH  - Stroke Volume
MH  - Ventricular Function, Left
COIS- Declaration of interest Dr Minges and Yongfei Wang receive salary support for 
      analytic services provided to the American College of Cardiology. Dr Lampert 
      reports research grants from Medtronic and Abbott Laboratories/St. Jude Medical 
      and serves on Medtronic advisory board and receives moderate honoraria. Dr 
      Rosenfeld reports fellowship support and stock ownership for Abbott Laboratories 
      and fellowship support from Boston Scientific and Medtronic. Dr Jacoby reports 
      being on the speaker's bureau and an advisory board for Alnylam and participating 
      in ongoing funded research with Alnylam; receiving research grant from Myokardia; 
      serving on an advisory board and steering committee for Myokardia; and receiving 
      consulting fees from Abbott. Dr Curtis has a contract with the American College 
      of Cardiology for his role as Senior Medical Officer, NCDR; receives salary 
      support from the American College of Cardiology, NCDR; receives funding from the 
      Centers for Medicare & Medicaid Services to develop and maintain performance 
      measures that are used for public reporting; and holds equity interest in 
      Medtronic. Dr Miller reports grants from Bracco and Eidos, grants and consulting 
      for Alnylam and Pfizer, outside the submitted work. Dr Freeman reports 
      Consulting/Advisory Board fees from Janssen Pharmaceuticals, Medtronic, Boston 
      Scientific and Biosense Webster. He receives salary/research support from the 
      American College of Cardiology, NCDR and the National Heart Lung and Blood 
      Institute. The remaining authors have no disclosures to report.
EDAT- 2021/12/31 06:00
MHDA- 2022/04/08 06:00
CRDT- 2021/12/30 20:11
PHST- 2020/09/09 00:00 [received]
PHST- 2021/12/19 00:00 [revised]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2021/12/30 20:11 [entrez]
AID - S0002-8703(21)00491-9 [pii]
AID - 10.1016/j.ahj.2021.12.011 [doi]
PST - ppublish
SO  - Am Heart J. 2022 Apr;246:21-31. doi: 10.1016/j.ahj.2021.12.011. Epub 2021 Dec 27.